Loading...
ERIS logo

Eris Lifesciences Community

NSEI:ERIS Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 5 Fair Values set on narratives written by author

Community Investing Ideas

ERIS logo
Eris Lifesciences

India's Shift To Branded Generics Will Expand Chronic Therapy Markets

Key Takeaways Eris is poised for revenue and margin expansion due to its chronic therapy pipeline, branded generics focus, and strategic capacity additions. Market growth is supported by deeper doctor engagement, tier 2/3 city expansion, and execution of international export strategies.

View narrative
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
₹1.86k
13.9% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
16.1% p.a.
Profit Margin
23%
Future PE
34.3x
Share price in 2028
₹2.65k